PuSH - Publikationsserver des Helmholtz Zentrums München: Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B<sub>2</sub> receptor antagonism.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Jakwerth, C.A. ; Feuerherd, M. ; Guerth, F. ; Oelsner, M. ; Schellhammer, L.* ; Giglberger, J. ; Pechtold, L.* ; Jerin, C. ; Kugler, L.* ; Mogler, C.* ; Haller, B.* ; Erb, A. ; Wollenberg, B.* ; Spinner, C.D.* ; Buch, T.* ; Protzer, U. ; Schmidt-Weber, C.B. ; Zissler, U.M. ; Chaker, A.

Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B₂ receptor antagonism.

J. Mol. Med. 100, 613-627 (2022)

Verlagsversion

Forschungsdaten

DOI

PMC

	Open Access Hybrid

Abstract
Metriken
Zusatzinfos

SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and epithelial mechanisms of the kinin-kallikrein-system at the kinin B₂ receptor level in SARS-CoV-2-infection that is of direct translational relevance. From acute SARS-CoV-2-positive study participants and -negative controls, transcriptomes of nasal curettages were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B₂R-antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays, and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo. Here, we report a broad and strong upregulation of kallikreins and the kinin B₂ receptor (B₂R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive study participants. A B₂R-antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero-E6 cells. B₂R-antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2, G protein-coupled receptor signaling, and ion transport in vitro and in a murine airway inflammation in vivo model. In summary, this study provides evidence that treatment with B₂R-antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B₂R-antagonists, like icatibant, in the treatment of early-stage COVID-19. KEY MESSAGES: Induction of kinin B₂ receptor in the nose of SARS-CoV-2-positive patients. Treatment with B₂R-antagonist protects airway epithelial cells from SARS-CoV-2. B₂R-antagonist reduces ACE2 levels in vivo and ex vivo. Protection by B₂R-antagonist is mediated by inhibiting viral replication and spread.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

5.606

0.000

PuSH - Publikationsserver des Helmholtz Zentrums München

Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism.

Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B₂ receptor antagonism.